AU · rank #11 · 2026-09-10
FRE
XETRA · EUR · $29.05B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.197 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.01 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 10 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $55.59 | +25.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +18.59% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +25.4% |
| 52w high | $51.53 |
| Market cap (USD) | $29.05B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Fresenius SE is a diversified European healthcare group operating hospital networks (Helios) and infusion/nutrition therapy (Kabi), generating €22.6B in 2025 revenue.
Rationale
With 91.7% revision agreement across 14 analysts, a 25.4% consensus upside, and 60-day EPS revisions trending positive, the analyst upgrade cycle thesis is well-supported by Q4 2025's 16% Core EPS growth and confirmed 2026 guidance.
Material risks
- 1The -6.68% last earnings surprise signals execution risk against elevated expectations — if 2026's moderating growth (4–7% organic vs. 9% in Q4) disappoints, the revision cycle can reverse sharply given 24.3% target price dispersion among analysts.
- 2The KGaA dual-class structure limits shareholder influence, and FX headwinds on constant-currency guidance could erode reported EPS growth materially given Fresenius's significant non-euro revenue exposure.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.